Minaris Advanced Therapies Executive and Leadership Team

Dash Ghattu, the Chief Executive Officer at Minaris Advanced Therapies, directs the overarching corporate strategy for cell and gene therapy manufacturing. Overseeing global expansion, the Chief Executive Officer ensures alignment between GMP manufacturing capabilities and the evolving needs of the biotechnology sector. This leadership role involves driving commercial growth while maintaining rigorous quality standards across all international facilities. By fostering partnerships with pharmaceutical innovators, Dash Ghattu accelerates the transition of complex therapies from early-stage development to commercial launch. The Chief Executive Officer maintains constant oversight of operational efficiency to support the company mission of providing life-changing treatments. Through strategic resource allocation, Ghattu secures the long-term market position of the organization within the competitive CDMO landscape. This executive leadership ensures that the company remains at the forefront of advanced testing and regulatory support, ultimately impacting patient outcomes on a global scale.

William Burckardt, the Chief Financial Officer at Minaris Advanced Therapies, manages the financial health and capital allocation strategies for the organization. Overseeing fiscal planning, the Chief Financial Officer ensures that resources are effectively directed toward expanding manufacturing capacity and enhancing biosafety testing capabilities. This leadership role involves providing financial oversight for global operations, ensuring that the company maintains the necessary investment to support long-term growth. By analyzing market trends, William Burckardt informs strategic decisions regarding commercial expansion and service offerings. The Chief Financial Officer drives financial discipline across all departments, supporting the company mission through sustainable growth and profitability. Through rigorous budget management, Burckardt ensures that the organization remains well-positioned to meet the evolving demands of the cell and gene therapy market. This executive leadership provides the stability required to deliver high-quality services to clients from early-stage development to commercial launch.

Darwin Richardson, the Chief Operating Officer at Minaris Advanced Therapies, manages the end-to-end execution of GMP manufacturing processes for cell and gene therapies. Overseeing production workflows, the Chief Operating Officer ensures that facilities maintain the highest standards of quality and compliance for CAR-T and vaccine production. This leadership role involves coordinating cross-functional teams to meet critical project milestones for biotechnology clients. By streamlining supply chain logistics, Darwin Richardson optimizes the delivery of complex therapies from development to commercial launch. The Chief Operating Officer drives continuous improvement initiatives to increase manufacturing capacity and operational throughput. Through rigorous oversight of facility performance, Richardson maintains the company reputation for excellence in the CDMO sector. This executive leadership supports the broader mission by ensuring that every manufacturing process adheres to strict regulatory requirements, ultimately facilitating the rapid availability of life-changing treatments for patients worldwide.

Ilya Koltover, the President, Minaris Advanced Testing at Minaris Advanced Therapies, directs the specialized biosafety and analytical testing services provided to the biotechnology industry. Overseeing the testing division, the President, Minaris Advanced Testing ensures that all analytical processes meet the stringent quality requirements necessary for cell and gene therapy development. This leadership role involves expanding the testing portfolio to include advanced assays for viral vectors and vaccines. By integrating testing services with manufacturing workflows, Ilya Koltover provides clients with a seamless end-to-end experience. The President, Minaris Advanced Testing drives operational excellence within the laboratory environment, ensuring rapid turnaround times and high-quality data. Through strategic focus on technical accuracy, Koltover supports the company mission of accelerating access to life-changing therapies. This executive leadership ensures that the organization remains a trusted partner for clients requiring rigorous testing and regulatory support throughout the product lifecycle.

Hiroto Bando, the President (Japan) at Minaris Advanced Therapies, directs the regional operations and strategic growth initiatives within the Japanese market. Overseeing local manufacturing and testing facilities, the President (Japan) ensures that all services align with the global standards of the organization while meeting specific regional regulatory requirements. This leadership role involves fostering strong relationships with local biotechnology partners and healthcare providers to expand the reach of cell and gene therapy services. By optimizing regional workflows, Hiroto Bando enhances the efficiency of manufacturing processes for CAR-T and other advanced therapies. The President (Japan) drives the integration of local expertise into the broader global network, ensuring consistent quality across all sites. Through effective regional management, Bando supports the company mission of accelerating patient access to life-changing treatments. This executive leadership ensures that the organization maintains a strong and compliant presence in the critical Japanese market.

Prakash Manwani, the Chief Information Officer at Minaris Advanced Therapies, architects the digital infrastructure required for secure and compliant cell therapy manufacturing. Overseeing data integrity across global facilities, the Chief Information Officer implements advanced systems to support biosafety testing and regulatory documentation. This leadership role involves integrating complex manufacturing data with client-facing platforms to ensure transparency throughout the development lifecycle. By optimizing cybersecurity protocols, Prakash Manwani protects sensitive intellectual property and patient data. The Chief Information Officer drives digital transformation initiatives that enhance operational efficiency and data-driven decision-making. Through the deployment of scalable cloud solutions, Manwani supports the rapid growth of the organization. This executive leadership ensures that all information systems remain fully compliant with international GMP standards, providing a robust foundation for the delivery of viral vectors and vaccines to the global market.

Shinobu Kuwae, the Chief Technology Officer at Minaris Advanced Therapies, directs the development of innovative manufacturing technologies for advanced cell and gene therapies. Overseeing process engineering, the Chief Technology Officer implements cutting-edge solutions to improve the scalability of viral vector and vaccine production. This leadership role involves collaborating with research teams to refine manufacturing protocols and enhance product quality. By evaluating emerging technologies, Shinobu Kuwae ensures that the company remains a leader in the CDMO space. The Chief Technology Officer drives technical excellence across all global sites, fostering an environment of continuous innovation. Through the application of advanced scientific expertise, Kuwae supports the transition of therapies from laboratory settings to large-scale commercial manufacturing. This executive leadership ensures that the organization maintains a competitive edge by providing clients with the most efficient and reliable technical support for their complex therapeutic programs.

Rachel Clarke, the Chief Legal Officer & General Counsel at Minaris Advanced Therapies, directs the legal and regulatory compliance framework for all manufacturing and testing operations. Overseeing corporate governance, the Chief Legal Officer & General Counsel ensures that all activities align with international health regulations and industry standards. This leadership role involves managing complex contractual agreements with biotechnology partners and protecting the intellectual property of the organization. By providing strategic legal guidance, Rachel Clarke mitigates risk and supports the successful execution of commercial projects. The Chief Legal Officer & General Counsel drives compliance initiatives that maintain the integrity of the company services, including CAR-T and viral vector manufacturing. Through proactive legal oversight, Clarke ensures that the organization operates within the bounds of global regulatory requirements. This executive leadership is essential for maintaining the trust of clients and ensuring the safe delivery of life-changing therapies to patients.